ANAVEX Life Sciences Corp. is a biopharmaceutical company engaged in the discovery and development of new drugs for the treatment of neurological diseases and cancer, utilizing its proprietary drug discovery SIGMACEPTOR™ platform. ANAVEX portfolio involves new sigma receptor compounds (ligands) in preclinical stage that target diseases of the Central Nervous System (CNS) and Cancer. The company’s lead drug candidate ANAVEX 2-73, targeting Alzheimer’s disease (AD) will enter first Human Clinical Trials (HTC) by September. In parallel, another three of Anavex’s compounds (melanoma, prostate cancer and epilepsy) will reach final preclinical stage later this year.